Globus Medical completed its previously-announced merger with NuVasive. The combined company will provide a highly comprehensive offering of musculoskeletal procedural solutions and enabling technologies.
The merger between Globus Medical and NuVasive combines their complementary global scale, expanded commercial reach, comprehensive portfolios in spine and orthopedics and increased operational capabilities. The merger also offers compelling upside revenue potential and a strong financial profile for value creation.
Globus Medical will discuss the closing and further detail during its 3Q23 earnings call in November.
We estimate the combined organization will generate over $2.4 billion in sales for 2023, with $1.7 billion coming from core spine products. The deal makes Globus the clear number two player in the spine market with a highly complementary portfolio and arguably spine’s best enabling technology ecosystem. However, the two organizations are far apart on culture and margins in a market segment where M&A integrations have a poor track record. The next two years will be crucial for Globus Medical.
“We’re thrilled to begin our journey together to create a leading global musculoskeletal company,” said Dan Scavilla, president and chief executive officer of Globus Medical. “With a relentless focus on changing patient lives, we’re combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally.”
Globus Medical completed its previously-announced merger with NuVasive. The combined company will provide a highly comprehensive offering of musculoskeletal procedural solutions and enabling technologies.
The merger between Globus Medical and NuVasive combines their complementary global scale, expanded commercial reach, comprehensive...
Globus Medical completed its previously-announced merger with NuVasive. The combined company will provide a highly comprehensive offering of musculoskeletal procedural solutions and enabling technologies.
The merger between Globus Medical and NuVasive combines their complementary global scale, expanded commercial reach, comprehensive portfolios in spine and orthopedics and increased operational capabilities. The merger also offers compelling upside revenue potential and a strong financial profile for value creation.
Globus Medical will discuss the closing and further detail during its 3Q23 earnings call in November.
We estimate the combined organization will generate over $2.4 billion in sales for 2023, with $1.7 billion coming from core spine products. The deal makes Globus the clear number two player in the spine market with a highly complementary portfolio and arguably spine’s best enabling technology ecosystem. However, the two organizations are far apart on culture and margins in a market segment where M&A integrations have a poor track record. The next two years will be crucial for Globus Medical.
“We’re thrilled to begin our journey together to create a leading global musculoskeletal company,” said Dan Scavilla, president and chief executive officer of Globus Medical. “With a relentless focus on changing patient lives, we’re combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally.”
Copy to clipboard 
